Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VIS954 MAD Trial in Healthy Participants
NCT06937593Phase 1Completed
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization
- Start
- Mar 2025
- Primary completion
- Feb 2026
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of VIS-954 (4 arms), sponsored by Otsuka Pharmaceutical Development & Commercialization. Primary endpoints: Incidence of treatment-emergent adverse events at 169 days, Maximum serum concentration at 169 days and 1 more. Started Mar 2025; status: completed.
02
Drugs
VIS-954
Beyond the preview
Go deeper on NCT06937593.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06937593.